- Home
- MMT vs AGEN Comparison
MMT vs AGEN Comparison
Compare MMT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMT
- AGEN
- Stock Information
- Founded
- MMT 1987
- AGEN 1994
- Country
- MMT United States
- AGEN United States
- Employees
- MMT N/A
- AGEN N/A
- Industry
- MMT Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMT Finance
- AGEN Health Care
- Exchange
- MMT Nasdaq
- AGEN Nasdaq
- Market Cap
- MMT 254.7M
- AGEN 87.7M
- IPO Year
- MMT N/A
- AGEN 2000
- Fundamental
- Price
- MMT $4.70
- AGEN $6.07
- Analyst Decision
- MMT
- AGEN Buy
- Analyst Count
- MMT 0
- AGEN 4
- Target Price
- MMT N/A
- AGEN $13.00
- AVG Volume (30 Days)
- MMT 86.5K
- AGEN 1.2M
- Earning Date
- MMT 01-01-0001
- AGEN 08-07-2025
- Dividend Yield
- MMT 8.58%
- AGEN N/A
- EPS Growth
- MMT N/A
- AGEN N/A
- EPS
- MMT 0.30
- AGEN N/A
- Revenue
- MMT N/A
- AGEN $99,524,000.00
- Revenue This Year
- MMT N/A
- AGEN $12.69
- Revenue Next Year
- MMT N/A
- AGEN N/A
- P/E Ratio
- MMT $15.33
- AGEN N/A
- Revenue Growth
- MMT N/A
- AGEN N/A
- 52 Week Low
- MMT $4.04
- AGEN $1.38
- 52 Week High
- MMT $4.70
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- MMT 63.93
- AGEN 67.49
- Support Level
- MMT $4.53
- AGEN $4.34
- Resistance Level
- MMT $4.73
- AGEN $5.22
- Average True Range (ATR)
- MMT 0.04
- AGEN 0.46
- MACD
- MMT 0.01
- AGEN 0.02
- Stochastic Oscillator
- MMT 85.00
- AGEN 93.01
About MMT MFS Multimarket Income Trust
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).